Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.59 |
| ▸ | PKM | P14618 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3207441 | 0.79 | FAAH (0.52) | TSHR | |
| SCHEMBL3209965 | 0.77 | LMNA (0.58) | PKMMEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL3221924 | 0.77 | HTR2C (0.42) | POLBPKMLMNA | |
| SCHEMBL3221859 | 0.75 | MEN1 (0.60) | POLBPKMMEN1KMT2AALDH1A1 | |
| SCHEMBL3213866 | 0.75 | HTR2C (0.55) | MEN1KMT2AMAPK1RAB9AMAPT | |
| SCHEMBL3224285 | 0.75 | HTR6 (0.50) | MAPTLMNASMN1; SMN2 | |
| SCHEMBL13598990 | 0.75 | PKM (0.72) | POLBPKMMEN1KMT2AALDH1A1 | |
| SCHEMBL3201949 | 0.74 | EPHX2 (0.50) | MAPK1TSHRHPGDEPHX2LMNA | |
| SCHEMBL3916331 | 0.74 | POLB (1.00) | POLBPKMMEN1KMT2AALDH1A1 | |
| SCHEMBL2042088 | 0.73 | POLB (0.77) | POLBPKMALDH1A1TSHRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | XIANG JASON SHAOYUN | 2010-02-04 | — | — | US | disclosed |
| US-7632838-B2 | 11-beta HSD1 inhibitors | WYETH (US) | 2009-12-15 | — | — | US | disclosed |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | HSD11B1, HSD3B1, HSD11B2 | POLB 1831/4885PKM 2924/4885MEN1 1354/4885 |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | HSD11B1, HSD11B2, HSD3B1 | POLB 2595/4885PKM 2798/4885MEN1 1687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.